Guggenheim Maintains Buy on Oruka Therapeutics, Raises Price Target to $125

Benzinga Newsdesk www.benzinga.com Positive 60.5%

Neg 0% Neu 0% Pos 60.5%

Guggenheim analyst Yatin Suneja maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $60 to $125.